COVID-19

Since last December 2019, an outbreak of a novel coronavirus disease (COVID-19; previously known as 2019-nCoV) was reported in Wuhan, China. COVID-19 has subsequently affected the global regions including Americas, Europe, Africa, Western Pacific, etc. Even though COVID-19 is an acute resolved disease, it can also be deadly, with a 2% case fatality rate. As of Mar 18, about 191,127 cases have been confirmed globally, with 7807 death cases. Now COVID-19 is an emerging, rapidly evolving situation.

Fig.1 Distribution of COVID-19 cases as of 18 March 2020.⁴

COVID-19 Patients’ Immune Response

A study just published in Nature Medicine reported the breadth of concomitant immune responses prior to one COVID-19 patient recovery, showing the body’s ability to fight against SARS-CoV-2 and recover from the infection. Scientists collected blood samples to study how the patient’s immune responses performed, and when the immune system activated. They found that increased antibody-secreting cells (ASCs), follicular helper T cells (T_FH cells), activated CD4⁺ T cells and CD8⁺ T cells and immunoglobulin M (IgM) and IgG antibodies which react with COVID-19-causing coronavirus SARS-CoV-2 were detected in blood before symptomatic recovery. These immune activities persisted for at least 7 days after the infection went away.

Fig.2 Immune responses prior to one COVID-19 patient recovery.¹

COVID-19 Recovered Patient-Derived Anti-SARS-CoV-2 Therapeutic Antibody Development

The published data provided evidence on the recruitment of a variety of immune cell populations, together with IgM and IgG SARS-CoV-2 binding antibodies in the patient’s blood before the resolution of symptoms, providing insights into the potential therapeutic antibody therapy to treat COVID-19. With extensive experiences and knowledge in antibody discovery and development, Creative Biolabs is confident in the anti-SARS-CoV-2 therapeutic antibody development program using blood samples from COVID-19 recovered patients. Empowered by Native™ Antibody Discovery and B cell sorting platform, we have been providing the quality native paired antibodies for over 10 years. Creative Biolabs can assist companies and academic investigators who are actively developing COVID-19 therapy with our Native™ Antibody Discovery platform.

Fig.3 Proposed immune responses during SARS-CoV-2 infection.²

Highlights

• End-to-end solutions for COVID-19 therapy discovery and development
• Antibody and immunotherapy Expert
• Extensive experiences

Creative Biolabs is seeking partners to co-develop the therapeutic monoclonal antibody program targeting SARS-CoV-2. As always, we are available for flexible discussions to see how we can collaborate and develop the research against COVID-19. Please don’t hesitate to contact us by email, telephone, or TC when you have any questions. Let’s work together to find solutions to this novel virus.

References

1. Thevarajan, I.; et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nature medicine. 2020, 26(4): 453-455.
2. Prompetchara, E.; et al. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pacific journal of allergy and immunology. 2020, 38(1): 1-9.
3. Xu, Z.; et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet respiratory medicine. 2020, 8(4): 420-422.
4. World Health Organization. Coronavirus disease 2019 (‎COVID-19)‎: situation report, 58. World Health Organization.2020.

For Research Use Only | Not For Clinical Use